Loading patent…
OwnerDaniel Chelsky, Paul Kearney +5inventors
InventorsDaniel Chelsky, Paul Kearney, Eustache Paramithiotis, Lyes Hamaidi, Leslie Kondejewski, Joel Lanoix, Patrice Hugo
Estimating the term…
Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.
An antibody or fragment thereof that specifically binds to a TAT-038 polypeptide.
A method of diagnosing an increased likelihood of developing a TAT-038-related disease or condition in a test subject, said method comprising analyzing nucleic acid molecules of the test subject to determine whether said test subject contains a mutation in a TAT-038 gene, wherein the presence of said mutation is an indication that said test subject has an increased likelihood of developing a TAT-038-related disease.
A probe for analyzing the TAT-038 nucleic acid molecules of an animal, said probe having at least 60% nucleic acid sequence identity to a sequence encoding a TAT-038 polypeptide or a fragment thereof, wherein said fragment encodes at least six contiguous amino acids and said probe hybridizes under high stringency conditions to at least a portion of a TAT-038 nucleic acid molecule.
A method of detecting the presence of a TAT-038 polypeptide in a sample, said method comprising contacting said sample with a TAT-038 binding molecule that specifically binds to a TAT-038 polypeptide and assaying for binding of said molecule to said polypeptide.
A method of detecting the presence of a mutant TAT-038 polypeptide in a sample, said method comprising contacting said sample with an antibody that specifically binds to a mutant TAT-038 polypeptide and assaying for binding of said antibody to said mutant polypeptide.
A kit for the analysis of a TAT-038 polypeptide, said kit comprising an antibody for analyzing the TAT-038 polypeptide of a test subject.
A method for preventing or ameliorating the effect of a TAT-038 deficiency, said method comprising administering to a subject having a TAT-038 deficiency a therapeutically-effective amount of a compound to prevent or ameliorate said effect of said TAT-038 deficiency.
A method for preventing or ameliorating the effect of a TAT-038 polypeptide excess, said method comprising administering a therapeutically-effective amount of a compound to a subject having a TAT-038 excess, wherein said compound is sufficient to prevent or ameliorate said effect of said TAT-038 polypeptide excess.
A substantially pure TAT-038 polypeptide or fragment thereof.
A substantially pure nucleic acid molecule comprising a sequence encoding a TAT-038 polypeptide, or fragment thereof.
A composition for inducing an immune response in a subject, said composition comprising a substantially pure TAT-038 polypeptide or fragment thereof in a pharmaceutically-acceptable carrier.
A method of inducing an immune response to a TAT-038 polypeptide, said method comprising the steps of:
A method of inducing an immune response in a subject comprising administering to said subject a composition comprising a TAT-038 polypeptide.
A pharmaceutical composition comprising (i) a TAT-038 polypeptide and (ii) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising (i) a compound that binds to a TAT-038 polypeptide and (ii) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising (i) a TAT-038 nucleic acid molecule and (ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.